Reals Pharmaceuticals Limited
Plot 1 Junaid Dosunmu Street,Central Business District, Alausa, P.0. Box 3560 Ikeja, Lagos, Nigeria.
Tel: + 234-1-774-1205
Fax: +234-1-263-0919

Brand Name



Pharmaceuticals Ltd, 26, Manoj Industrial Premises, G.D. Ambekar Marg. Wadala, Mumbai-400 031

Therapeutic Class


Dosage Form, Composition & NAFDAC Registration Number (NRN)

Tablet (NRN: 04-7202): Each uncoated tablet contains: Frusemide BP 40 mg.

Pack size: Blister pack of 10 tablets, 10 blister packs in a carton.



Frusemide is a potent diuretic acting primarily on the medullary portion of the ascending limb of the Loop of Henle to inhibit sodium and chloride reabsorption.

Frusemide reduces the renal excretion of uric acid and the effects of frusemide are decreased by probenecid probably by reducing the amount of diuretic available for action within the ascending limb of the Loop of Henle.

Frusemide causes an increase loss of potassium in the urine and also increases the excretion of ammonia by the kidney.


Acute pulmonary oedema;

Chronic congestive cardiac failure;


Oedema due to renal failure or due to nephrosis;

Oedema due to liver cirrhosis;


Forced diuresis in treatment of poisoning.


Frusemide is contra-indicated in patients with anuria and in patients with a history of hypersensitivity to frusemide.

Frusemide should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.



Adverse Effects

Nausea and gastric discomfort may occur but are rarely severe enough to necessitate cessation of treatment. Rapid diuresis may cause acute discomfort and incontinence in some elderly patients.

Frusemide can cause skin rashes and if the drug is suspected as the cause of a rash, treatment should be stopped. A small number of cases of exfoliative dermatitis have been associated with use of frusemide.

Frusemide, as other loop diuretics, may cause ototoxicity. The deafness caused by frusemide is usually reversible when the drug is stopped

However, irreversible ototoxicity has been reported. This adverse effect most often occurs in patients with renal failure who are treated with high intravenous doses of frusemide. The risk of ototoxicity is increased when the drug is given concomitantly with aminoglycoside antibiotics.

Prolonged use of high doses of frusemide in patients with severe disease, coupled with limitation of salt intake may lead to hyponatraemia.

Diuretics, including frusemide may affect plasma lipid concentrations. Serum triglyceride and, to a lesser degree, serum cholesterol concentrations increased concomitantly with a rise of low density lipoprotein (LDL) cholesterol and a decrease of high density lipoprotein (HDL) cholesterol.

Dosage & Administration

Oral treatment with frusemide is usually begun with 20-40 mg once to three times daily and the doses are increased depending on the therapeutic response. In general oral doses of 160-320 mg daily need not and should not be exceeded.

However, in patients with renal failure oral doses of up to 1000 mg per day may be required.

Daily doses of 1-3 mg/kg may be given to children.

Storage/Handling Recommendations

Review Date

2016-09-01 04:39:49